Tumor Infiltrating Lymphocytes
Trials 81 · started per year
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07628894 Background | Dec 2026 → Jul 2027 expected | cutaneous melanoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03158935 Background | Jul 2017 → Aug 2020 | melanoma, ovarian carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT00003665 Background | Apr 1999 → Oct 2002 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01369888 Background | May 2011 → May 2014 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00046852 Background | Dec 2001 → Nov 2004 | infectious disease, plasma cell myeloma | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02500576 Background | Aug 2015 → Oct 2022 | cutaneous melanoma, metastatic melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00006113 Background | Jun 1999 → May 2003 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06743126 Comparator | Jan 2025 → Jan 2028 expected | cutaneous melanoma | Immatics US, Inc. | Recruiting | No outcome recorded |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 90 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Infiltrating Lymphocytes | “adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can...” PMID 23650429 ↗ May 201327“Accumulating evidence shows that tumor-infiltrating lymphocytes (TILs) selected for tumor recognition and greatly expanded in vitro are effective for treating cervical cancer patients.” NCT04443296 ↗ “Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.” NCT04611126 ↗ “Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.” NCT03374839 ↗ “NSC-373364 LAK Lymphokine-Activated Killer Cells TIL Tumor Infiltrating Lymphocytes” NCT00002535 ↗ “Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells).” NCT00937300 ↗ “Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells).” NCT00937625 ↗ “autologous tumor infiltrating lymphocytes (TIL)” NCT00002733 ↗ “TILs（Tumor Infiltrating Lymphocytes）” NCT06455917 ↗ “TILs（Tumor Infiltrating Lymphocytes）” NCT04919616 ↗ |
| Known as | AMTAGVI | “Administration of CD8 PET-guided infusion of lifileucel (AMTAGVI) on Day 0 following completion of the lymphodepleting chemotherapy regimen.” NCT07700121 ↗ |
| Known as | Autologous TIL | “Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.” NCT04165967 ↗1“Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.” NCT05869539 ↗ |
| Known as | Autologous Tumor Infiltrating Lymphocytes (TIL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07183852 ↗ |
| Known as | Autologous Tumor Infiltrating Lymphocytes LN-145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03449108 ↗ |
| Known as | lifileucel | “tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel” NCT07288073 ↗12“Infusion of lifileucel is then given” NCT05398640 ↗ |
| Known as | LN-144 | “Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process.” NCT05607095 ↗2“Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process.” NCT05640193 ↗ |
| Known as | LN-144, TIL, autologous tumor-infiltrating lymphocytes | “LN-144, TIL, autologous tumor-infiltrating lymphocytes” NCT03645928 ↗ |
| Known as | LN-145 | “Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process.” NCT05607095 ↗ |
| Known as | LN-145/LN-144 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06566092 ↗ |
| Known as | TBio-4101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05576077 ↗ |
| Known as | TDTL | “tumor-derived T-lymphocytes (TDTL)” NCT00301730 ↗ |
| Known as | therapeutic tumor infiltrating lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00301730 ↗ |
| Known as | TIL | “adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can...” PMID 23650429 ↗ May 201310“Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.” NCT04967833 ↗ “Tumor infiltrating lymphocytes (TIL) are white blood cells that have been taken from tumor tissue.” NCT01369875 ↗ “NSC-373364 LAK Lymphokine-Activated Killer Cells TIL Tumor Infiltrating Lymphocytes” NCT00002535 ↗ “treatment with tumour infiltrating lymphocytes (TIL) and interferon-alpha (IFNa).” PMID 33234662 ↗ Nov 2020 “Biological: Tumor Infiltrating Lymphocytes (TIL)” NCT03467516 ↗ “autologous tumor infiltrating lymphocytes (TIL)” NCT00002733 ↗ “Tumor Infiltrating Lymphocytes (TIL)” NCT00863330 ↗ “Tumor Infiltrating Lymphocytes (TIL)” NCT04766320 ↗ |
| Known as | TILs | “Accumulating evidence shows that tumor-infiltrating lymphocytes (TILs) selected for tumor recognition and greatly expanded in vitro are effective for treating cervical cancer patients.” NCT04443296 ↗7“Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.” NCT04766320 ↗ “Tumor-infiltrating lymphocytes (TILs) therapy is an advanced form of adoptive cell therapy that harnesses the patient's immune cells to fight cancer.” NCT06532812 ↗ “TILs are expanded from tumor resections or biopsies, and after ex vivo stimulation, activation and extensive expansion, are reinfused to patients” NCT05649618 ↗ “autologous TILs, a type of white blood cell that recognizes tumor cells and enters them, thereby causing tumor cells to break down.” NCT03158935 ↗ “Tumor-infiltrating lymphocytes (TILs) therapy is an innovative form of adoptive cell therapy” NCT06538012 ↗ |
| Known as | Tumor infiltrating lymphocyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04538313 ↗ |
| Known as | Tumor Infiltrating Lymphocytes (TIL) | “Tumor Infiltrating Lymphocytes (TIL)” NCT01701674 ↗ |
| Known as | tumor-derived T-lymphocytes | “tumor-derived T-lymphocytes (TDTL)” NCT00301730 ↗ |
| Action | Deplete | “causing tumor cells to break down” NCT03158935 ↗ |
| Modality | Cell therapy | “IL-2-activated TIL” NCT00002535 ↗ |
| Route | Other | “intracavitary cytotoxic T lymphocytes” NCT00002572 ↗ |